▶ GHRP-2 · SUBTOPIC · MECHANISM
GHRP-2 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Hexapeptide ghrelin receptor (GHS-R1a) agonist. Drives pituitary GH release with mild concomitant cortisol and prolactin elevation. Lower appetite stimulation than the structurally related GHRP-6.
PHARMACOKINETIC HALF-LIFE
Reported half-life for GHRP-2: ~15-60 minutes. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
GHRP-2 is a defined sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
GHRP-2 is tagged in 1 mechanism category on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Pralmorelin approved as a diagnostic agent in Japan for GH-deficiency testing. Reliable acute GH-response biomarker.
Well-characterized GHS-R1a binding affinity (Bowers, Smith et al.). Lower appetite signal than the structurally related GHRP-6.
No completed long-term Phase 3 trials for body-composition endpoints.
MECHANISM Q+A
▶ What is GHRP-2?
GHRP-2 (also called pralmorelin) is a synthetic hexapeptide ghrelin / GHS-R1a receptor agonist that triggers pulsatile GH release from anterior-pituitary somatotrophs. It is approved as a diagnostic agent for GH-deficiency testing in Japan.
▶ GHRP-2 vs GHRP-6 · what's the difference?
Both are hexapeptide ghrelin receptor agonists. GHRP-2 has lower appetite signal than GHRP-6 due to differential downstream signaling at the GHS-R1a. GHRP-2 is preferred where appetite stimulation is unwanted; GHRP-6 is preferred where appetite stimulation is part of the research design.
▶ What is the half-life of GHRP-2?
Approximately 15-60 minutes plasma half-life. Multiple daily administrations are needed for sustained GH-axis stimulation in research protocols.
▶ How does GHRP-2 work?
GHRP-2 binds the ghrelin receptor (GHS-R1a) on anterior-pituitary somatotrophs and arcuate-nucleus neurons. The pituitary engagement triggers GH release; the hypothalamic engagement produces mild appetite stimulation (less than GHRP-6, more than ipamorelin).
▶ Why is GHRP-2 paired with a GHRH analog?
Ghrelin-receptor activation alone produces a smaller GH pulse than dual-pathway activation. Pairing with a GHRH analog (CJC-1295 No DAC or sermorelin) engages an independent upstream pathway and amplifies the pulse synergistically.
CITED LITERATURE
- Bowers CY, Reynolds GA, Durham D, et al.. Growth hormone-releasing peptide-2: A diagnostic agent for pediatric GH deficiency. Endocrine 2001. link
- Smith RG, Van der Ploeg LH, Howard AD, et al.. Pharmacology and effects of growth hormone-releasing peptides. Endocr Rev 1997. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25